# Effect of *Bacillus coagulans* Unique IS-2 in Inflammatory Bowel Disease (IBD): A Randomized Controlled Trial

1

2

4

5 6

7

8

9 10

11 12

13 14

15

16

17

18

19

20

21

22 23

24

25

26

27

28

29

30

31

32

33

34

35 36

37

38

39 40 V Deepak Bamola<sup>1</sup>, Divya Dubey<sup>1</sup>, Projoyita Samanta<sup>1</sup>, Saurabh Kedia<sup>2</sup>, Ratna Sudha Madempudi<sup>3</sup>, Jayanthi Neelamraju<sup>3</sup>, Vineet Ahuja<sup>2</sup>, Rama Chaudhry<sup>1</sup>\*

 Department of Microbiology, <sup>2</sup> Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India
 Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India
 \*Corresponding author

#### **Abstract**

Probiotic intervention is an important approach for the treatment and health restoration in inflammatory bowel disease (IBD). A study was conducted to assess the effect of Bacillus coagulans Unique IS-2 in IBD patients. Recruited subjects were given either probiotic B. coagulans Unique IS-2 or placebo for 4 weeks as per randomization. Survival of the given probiotic strain in GI, presence of beneficial gut bacteria, serum cytokines, serum serotonin and serum dopamine, symptoms of disease, physical, behavioral and psychological parameters of the subjects were evaluated before and after intervention. In this study B. coagulans Unique IS-2 was well tolerated with no severe adverse events in IBD patients and demonstrated good survival in GI tract by significantly high detection in probiotic treated group (p <0.001). Significant enhancement in beneficial Lactobacilli was observed in probiotic treated group (p <0.01). Metagenomic analysis also showed an increase in the abundance of bacterial genera Bacillus, Lactobacillus, Bifidobacterium, Faecalibacterium, Bacteroides, Megamonas, Lachnospira, Blautia, Alistipes and decrease in Sutterella, Dialister, Roseburia and Megasphaera was observed in the post intervention samples in the treatment group. Increased secretion of cytokine IL-10 and variable decrease in the secretion of IL-6, IL-1β, TNF- α, IL -17 and IL -23 was observed in in the probiotic treated group. Post intervention change in serum serotonin and serum dopamine was not significant in both the groups. A reduction in the severity of disease symptoms and improvement in the physical, behavioral and psychological parameter was observed in the probiotic treated group. The observed results demonstrated that B. coagulans Unique IS-2 with SMT was effective in adult IBD patients. Study was registered with Clinical Trials Registry India (CTRI) - (registration no.- CTRI/2019/11/022087).

**Keywords:** Inflammatory bowel disease (IBD), Gut Microbiota, Probiotic, *Bacillus coagulans*, Cytokines, Randomized Controlled Trial (RCT)

41 Introduction

Inflammatory bowel disease (IBD) is a gastrointestinal (GI) disease characterized by chronic inflammation. The incidence of IBD is rising all over the world<sup>1</sup> including Asia<sup>2</sup>. Across the globe India is projected to have one of the highest IBD burden in spite of having lower prevalence as compared to the West<sup>3,4</sup>. IBD significantly diminishes the quality of life of the affected individuals by disturbing health, daily work, education, and social relationships which cause a considerable impact on health and economy<sup>5</sup>. Etiology and pathogenesis of IBD is multi-factorial and involves genetics, ethnicity, diet, lifestyle, environmental factors, immunity and gut microbiota of the individual<sup>6,7</sup>. Higher stress level and disturbance in psychology in IBD patients may trigger the inflammation and increases the severity of disease<sup>8</sup>.

The human gut microbiota has demonstrated physiological functions associated with homeostasis, nutrition, immunity and defense of the host. Normally the gut maintains a homeostatic condition but in IBD this homeostasis gets disturbed and leads to intestinal inflammation<sup>9</sup>. Down-regulation of the immune responses may allow the damaged site to heal and reset the normal physiological functions<sup>7</sup>. Alteration in the gut microbiota, referred to as dysbiosis, plays a key role in the pathogenesis of IBD<sup>10,11</sup>. Dysbiosis may occur in both inflamed and non-inflamed areas in patients<sup>12</sup> and is well recognized sign of IBD<sup>13</sup>. Modification of gut microbiota with probiotic intervention to attenuate inflammatory activity and prevent relapses in IBD are considered as an important approach for treatment and health restoration in IBD<sup>11,14</sup> by relieving intestinal dysbiosis and GI inflammation<sup>10</sup>.

GI disorders modulate the gut function and influence the emotional and cognitive factors including mood, anxiety, pain and negative effects, decision making, restlessness. This change in emotional and cognitive factors may be associated with serum serotonin and dopamine in IBD patients<sup>15</sup>. The lowering of serotonin levels can result in mood disorders, such as anxiety or depression and hence consider playing an important role in regulating physical and psychological symptoms<sup>16</sup> and activation of immune response and gut inflammation<sup>15</sup>. Dopamine is an important neurotransmitter which affects behavior, psychology, immune functions and GI functions and its unregulated production in IBD is already reported<sup>17</sup>. Evaluation of these factors has turn out to be an important factor to monitor the severity of the disease. Gut microbiota and probiotics have demonstrated the effect on behavior, psychology, mood, and cognition<sup>18,19</sup>.

 Bacillus strains are stable at room temperature and hence gaining a lot of attention. B. coagulans is a spore-forming, gram-positive, non-pathogenic, facultative anaerobic, lactic acid-producing bacteria and resistant to high temperatures<sup>20</sup>. B. coagulans Qualified Presumption of Safety (QPS) list<sup>21</sup> and has been reported Generally Recognized as Safe (GRAS) and considered safe by European Union Food Safety Authority (EFSA) and US Food and Drug Administration (FDA). B coagulans Unique IS-2 (ATCC PTA-11748, MTCC 5260) is a shelf-stable, resistant to bile acids and acidic conditions of the stomach, clinically established probiotic strain and with proven safety and efficacy in the treatment of constipation, diarrhea<sup>22-25</sup> bacterial vaginosis<sup>26</sup> and irritable bowel syndrome (IBS)<sup>27</sup>. In this study we assessed the effect of B coagulans Unique IS-2 on adults with inflammatory bowel disease (IBD) receiving standard medical treatment (SMT). Survival of the given probiotic B coagulans Unique IS2 in the gut, presence of beneficial gut bacteria, serum cytokines, serotonin and dopamine, IBD symptoms, physical and psychological parameters were evaluated before and after intervention.

88 Methodology

- Study design: Randomized, double blind, placebo controlled trial. Study was registered
   with Clinical Trials Registry (CTRI) India (CTRI/2019/11/022087).
- 92 Site: Outpatients from a tertiary care hospital.

89

115

116

117

118119

- Ethical approval and written informed consent: Ethical approval for the study was
   obtained from Institute Ethics Committee of AIIMS, New Delhi, India (Ref –
   IEC.478/07.10.2016.OP-7). Expected duration of participation, expected benefits,
   associated risks, and maintenance of confidentiality of records were explained to each
   participant and a written informed consent was obtained before enrollment in the study.
- 98 **Subject / Selection of patients**: Clinically diagnosed adult patients of ulcerative colitis 99 (UC) with mild to moderate severity between age group (18-60 years) under standard Medical treatment (SMT) patients were included. Simple Clinical Colitis Activity Index 100 (SCCAI) score<sup>28</sup> was used to quantify UC disease activity. SCCAI score was calculated 101 102 by evaluating different disease symptoms including bowel frequency, urgency of defecation, blood in stool, abdominal cramps and general wellbeing of the patients. SMT 103 104 for the enrolled patient in this study was 5-aminosalicylic acid (5-ASA) - Sulfasalazine (3 105 grams/day) or Mesalamine 800 mg orally 3 times a day.
- Inclusion criteria: (a) Adult patient clinically diagnosed with Ulcerative Colitis (UC), (b)
   patients of either sex of the age range from 18-60 year, (d) patient ready to participate in
   the study and giving written consent, (e) patient visiting to Out Patient Department (OPD)
   of AIIMS for treatment.
- Exclusion criteria: (a) Patient diagnosed with any kind of carcinoma, (b) Patient diagnosed with any other gastrointestinal disease, (c) Patient suffering from Immunodeficiency disorder, (d) Patient is taking any probiotic drug/ or having consumed probiotic in the last one month, (e) patient not taking food through oral route, (f) Patient having undergone any kind of gastrointestinal surgery in the last three month.
  - Enrolment of patients: After establishing the eligibility on screening, a total of 100 patients were recruited and randomized. Patients were called for baseline visit (day 0). Medical history, medications, physical examination and vital signs were assessed during hospital visit. *B. coagulans* Unique IS-2 (2billion-CFU/capsule) twice in day (total 4 billion CFU / per day) or placebo (matching in size and appearance, contained only excipient, maltodextrin) twice in a day was given to qualified patients for 4 weeks followed by observation and telephonic follow-up of dose compliance.

- Sample size determination: Statistical software STATA (Version 14, USA) was used for
   sample calculation. To identify presence of proportion difference the assumption was
   made that minimum of 118 subjects required to be screened and 94 patients required
   assessing the endpoint in the study which will reject the null hypothesis.
- Intervention: Fully characterized FDA / DCGI/ FSSAI approved probiotic strain *Bacillus* coagulans Unique IS-2 (ATCC PTA-11748, MTCC 5260) was used as an intervention
   agent in this study for 4 weeks along with placebo as per randomization. The patients
   were explained to consume one capsule post meal twice a day for 4 weeks along with the
   SMT. The compliance was ensured by telephonic follow-up and scheduled hospital visits.
- Randomization: Computerized permuted blocks randomization was done in 1:1 ratio and generated by nQuery clinical trial design platform / Sample Size Software. It consisted of two phases: screening, baseline visit 1 (week 0 / day 0), visit 2 (1 week after completing intervention / week 5). The randomization codes were kept blinded.
- 135 Outcome measures: The efficacy outcomes were measured after administration by (i) detection of Bacillus coagulans Unique IS-2, (ii) Change in beneficial Lactobacillus and 136 137 other gut microbiota, (iii) Change in pro and anti-inflammatory cytokines, (iv) Change in 138 symptoms of the disease, (v) Change in serum concentration of serotonin and dopamine, 139 (vi) Changes in physical and psychological parameters. Each participant was requested to 140 answer the designed questionnaire for the assessment of physical, behavioral and psychological parameters as per the Hopkins Symptom Checklist (HSCL): A self-report 141 symptom inventory<sup>29,30</sup>. Physical parameters including muscle stiffness, heartburn, 142 143 headache, shakiness, sleep problem, difficulty in completing work, procrastination, overwhelming, feeling of depression, trouble relaxing, nervousness, poor concentration, 144 restlessness and quick temper were evaluated. Parameters were evaluated based on scores, 145 the decrease in the score indicating the reduction in the severity of symptoms and increase 146 147 in the score indicating an augmentation in the severity of the symptom.
- Safety evaluation: Safety of investigational product was assessed by adverse event
   reporting. During hospital visit of the patient physical examination, monitoring of vital
   signs and routine laboratory investigations.
- Sample collection and processing: A stool sample in a sterile container and a blood sample in a plain vial were collected from each enrolled subject before and after intervention. Stool samples were aliquoted and processed for microbial identification and bacterial DNA isolation. Blood samples were processed for serum separation for cytokine assays, serotonin and dopamine concentration.

156 **Microbial culture and identification:** B coagulans Unique IS-2 and Lactobacillus spp. were checked in each patient before and after intervention using different bacterial media. 157 158 Mueller Hinton (MH) broth and agar (Difco Laboratory, Detroit, MI) was used for the cultivation of Bacillus strains. Sample were incubated for 24 hours at 37°C in MH broth 159 and then plated on MH agar plate. de Man, Rogosa and Sharpe (MRS) broth and agar 160 161 (Difco Laboratory, Detroit, MI) was used to grow Lactobacillus. The stool sample were 162 incubated for 48 hours at 37°C in MRS broth in Anaerobic Glove Box (Anaerobic 163 Workstation-Whitley DG250-DonWhitley Scientific, United Kingdom) in anaerobic condition and then plated on MRS agar plate. The isolated colonies were identified by 164 standard culture and biochemical method, matrix-assisted laser desorption / ionization-165 166 (MALDI-and the mass analyzer is time-of-flight (TOF) analyzer (bioMérieuxInc, USA) 167 and molecular method.


- Molecular identification of Bacteria: B. coagulans was identified via 16S rRNA 168 169 sequencing using published primers: forward 5'-ACAGGGCTTTCAGATACCCG-3' and reverse 5'-CGGGGATCCGTCCATCAAAA-3'. Sequence similarity was checked using 170 171 BLAST, NCBI and it was 96% identical. A known strain of B. coagulans Unique IS-2 172 was used as a positive control. The reaction mixture consisted of 0.5µl of dNTP (10mM), 173 0.5ul of DNA template (177ng/µl), 2.5 µl of reaction buffer (10X) with MgCL2, 0.5ul of each of primers (pm/µl), 0.5µl of 5U/µlTaq DNA polymerase (Thermo Scientific, USA) 174 and 20 µl of nuclease free H<sub>2</sub>O. Denaturation was done at 94°C for 5min, followed by 30 175 cycles consisting of, 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min which has been 176 177 ended by a final amplification step at 72°C for 8min, using the PCR machine (Applied Biosystems, USA). PCR product was analyzed by the electrophoresis in 1% agarose gel 178 179 and gel bands were observed and recorded using via Gel Doc System (BioRad, USA).
- Next generation sequencing (NGS) of Gut microbiota-

- Fecal samples collection and DNA isolation: Fecal samples were collected in sterile container and processed for DNA isolation. Total DNA was extracted by using QIAamp DNA Stool Mini Kit (Qiagen) with some modification to increase DNA yield<sup>31</sup>. The quality and quantity of DNA was checked by Nanodrop (TECAN Nano quant). 16S rRNA amplicon sequencing was performed using Illumina MiSeq® sequencing system (Illumina, San Diego, CA, USA).
- Sequencing Methodology: Bacterial 16S rRNA hyper variable regions V3-V4 were
   amplified using V3-V4F (CCTACGGGNGGCWGCAG) and V3-V4R
  - amplified using V3-V4F (CCTACGGGNGGCWGCAG) and V3-V4R (GACTACHVGGGTATCTAATCC) primers. 25ng of DNA was used for PCR

- amplification using KAPA HiFi HotStart Ready Mix. The PCR was performed with standard protocol and the amplicons were purified using Ampure beads to remove unused primers. The amplicon product was amplified with Illumina primers to generate sequencing libraries. Qubit dsDNA assay kit was used for libraries preparation. Sequencing was done using Illumina Miseq with 2x300PE sequencing kit. The sequence data quality was checked using FastQC and MultiQC software.
- 196 **Data Analysis:** The analysis was done as per standard methodology<sup>32</sup>. Only QC passed reads were transferred into mothur and the pairs were aligned. The ambiguous contigs 197 were rejected and duplicates were merged. Chimeric sequences were identified by a 198 199 known reference and UCHIME algorithm was used. Using Silva v.132 database final 200 filtered contigs were classified into taxonomical outlines and clustered into Operational 201 Taxonomic Unit (OTUs) and abundance was calculated. Alpha diversity was assessed for 202 richness and relative abundance of bacteria. Chao1 and ACE indices were used for 203 richness and Shannon, Simpson, and Fisher were used for both richness and relative 204 Kruskal-Wallis rank sum test was carried out to identify statistically abundance. 205 significant difference among OTUs abundance between groups.

# **ELISA for Cytokines, serum serotonin and dopamine:**

- 207 Serum samples were tested and quantified for IL10, IL6, IL17, IL23, IL 1β, TNF, serum 208 serotonin and dopamine as per standard protocol and manufacture's instruction (Fine Test, 209 Fine Biotech Co. Ltd). In brief, standards and test samples were added to 96 well plates and incubated at 37°C for 90 min. After incubation, wells were washed with wash buffer 210 211 and secondary antibody were added and incubated at 37°C for 60 min. Further, wells were washed and HRP-Streptavidin was added and incubated at 37°C for 30 min. Multiple 212 washing was done with the wash buffer to wash unbound conjugates. TMB substrates 213 214 were used to visualize HRP enzymatic reaction. Absorbance at 450 nm has been 215 measured using the microplate reader (Nanodrop, Nanoquant Infinite M 200 Pro (Texan, 216 Austria GmbH) and the concentration were calculated.
- Data analysis: Here we have reported the analysis of data of the patients of ulcerative colitis (UC). Data from 48 subjects in treatment group and 49 subjects in placebo group were analysed. Statistical analysis was done by STATA statistical software (Version 14, USA). Statistical evaluation of parameters was assessed by Chi-square / two sample *t*-test and p value < 0.05 was considered as statistically significant.



257 Results

## Survival of *Bacillus coagulans* Unique IS2 in the gut

The samples of the enrolled subjects in the both treatment and placebo group were assessed for the presence of *Bacillus coagulans* Unique IS-2 before and after treatment. No *B coagulans* was detected in pre-treatment sample in both the groups. In the probiotic treated group *B coagulans* was detected in 65.21 % subjects by microbial culture method and 76.08 % subjects by molecular method which was significant as compared to placebo (p <0.0001). The samples from the subjects of placebo group were also assessed for the presence of *B coagulans* with no *B coagulans* being detected in placebo group by both microbial and molecular methods. These results indicate that the probiotic strain *B coagulans* Unique IS-2 was able to survive in GI tract of recruited IBD patients.

# Detection of beneficial Lactobacilli by microbial culture method


The samples of the enrolled IBD patients in both probiotic treated group and placebo group were assessed for the presence of beneficial Lactobacilli, before and after intervention. Results revealed that in the probiotic treated group, beneficial *Lactobacilli* were detected in 54.34 % and 78.26 % patients before and after intervention respectively. In the placebo group beneficial *Lactobacilli* were detected in 52.08 % and 47.91 % of patients before and after intervention respectively. The detection of beneficial *Lactobacilli* after intervention in the probiotic treated group was significantly high (p <0.01) which indicated that the probiotic strain *Bacillus coagulans* Unique IS-2 was able to enhance the presence of beneficial *Lactobacilli* in recruited IBD patients.

#### Next generation Sequencing (NGS) and Metagenomic analysis of gut microbiota

**Phyla:** Operational Taxonomic Unit (OTUs) were calculated for different bacterial taxon including phyla, class, orders, families, genera and species before and after intervention in both probiotic treated and placebo group. Analysis revealed phylum Firmicutes Bacteriodetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were abundant in both the groups. The average % OTUs of phylum *Firmicutes* were in 33.13% and 36.23% in pre and post intervention sample respectively in treatment group and 37.90% and 42.89% in placebo group. The average % OTUs of phylum *Bacteriodetes* were in 40.12% and 40.28% in pre and post intervention sample respectively in treatment group and 32.49% and 40.28% in pre and post intervention sample respectively in placebo group. OTUs of phylum *Bacteriodetes* were significantly increased in post intervention sample in

placebo group. The average % OTUs of phylum *Proteobacteria* were in 12.90% and 7.50% in pre and post intervention sample respectively in treatment group and 16.75% and 6.21% in placebo group. The average % OTUs of phylum *Actinobacteria* were in 6.64% and 4.29% in pre and post intervention sample respectively in treatment group and 8.62% and 2.04% in placebo group. Decrease in OTUs of phylum *Proteobacteria* and phylum *Actinobacteria* was significant in the treatment group. The average % OTUs of phylum *Euryarchaeota* were in 1.02% and 2.36% in pre and post intervention sample respectively in treatment group and 2.03% and 0.55% in placebo group. OTUs of phylum Euryarchaeota were increased in post intervention sample in treatment group and decreased in placebo group. The average % OTUs of phylum Verrucomicrobia were in 0.01% and 0.04% in pre and post intervention sample respectively in treatment group and 0.96% and 0.10% in placebo group. OTUs of phylum Verrucomicrobia were increased in post intervention sample in treatment group and decreased in placebo group.

Figure 1: Abundance of major bacterial phyla



<u>Class:</u> The average % OTUs of class Bacteroidia were 40.11% and 40.27% in pre and post intervention sample respectively in treatment group and 32.48% and 43.63% pre and post intervention sample respectively in placebo group. An increase in OTUs of class Bacteroidia

was significant in the placebo group. The average % OTUs of class Clostridia were 15.20% and 22.09% in pre and post intervention sample respectively in treatment group and 20.79% and 28.82% in pre and post intervention sample respectively in placebo group. The average % OTUs of class Gammaproteobacteria were 12.87 % and 7.41% in pre and post intervention sample respectively in treatment group and 16.72% and 6.16% respectively in placebo group. The average % OTUs of class Negativicutes were 7.96% and 6.35% in pre and post intervention sample respectively in treatment group and 3.49% and 7.22% respectively in placebo group. A decrease was observed in OTUs of class Negativicutes in post intervention samples of treatment group and an increase in post intervention samples in placebo group. The average % OTUs of class Methanobacteria were 1.02% and 2.36% in pre and post intervention sample respectively in treatment group and 2.03% and 0.55% in placebo group. An increase in OTUs of class Methanobacteria in post intervention samples was observed in treatment group and decrease in OTUs of class Methanobacteria in placebo group. The average % OTUs of class Actinobacteria were 3.49% and 1.81% in pre and post intervention sample respectively in treatment group and 7.76% and 1.64% pre and post intervention sample respectively in placebo group.

Figure 2: Abundance of major bacterial classes

310

311

312

313

314

315

316

317

318

319

320

321


322

323

324

325

326



**Order:** The average % OTUs of Bacteroidales were 39.94% and 40.03% in pre and post intervention sample respectively in treatment group and 32.37% and 43.46% in placebo group. A significant increase in OTUs of order Bacteroidales in post intervention samples was observed in placebo group. The average % OTUs of order Clostridiales was 15.19% and 22.08% in pre and post intervention sample respectively in treatment group and 20.79% and 28.81% in placebo group. The average % OTUs of order Selenomonadales was 8.02% and 6.30 % in pre and post intervention sample respectively in treatment group and 3.49% and 7.22% in placebo group. A decrease in OTUs of order Selenomonadales in post intervention samples in treatment group and increase in post intervention samples in placebo group. The average % OTUs of order Lactobacillales was 1.67% and 2.49% in pre and post intervention sample respectively in treatment group and 10.66% and 3.82% in placebo group. An increase in OTUs of order Lactobacillales was observed in post intervention samples in treatment group and decrease in post intervention samples in placebo group. The average % OTUs of order Erysipelotrichales was 7.00% and 5.03% in pre and post intervention sample respectively in treatment group and 2.48 % and 2.48% in placebo group. A decrease in OTUs of order Erysipelotrichales in post intervention samples in treatment group and increase in placebo group were observed. The average % OTUs of order Bifidobacteriales were 1.74% and 3.55% in pre and post intervention sample respectively in treatment group and 7.71% and 1.61% respectively in placebo group. An increase in OTUs of order Bifidobacteriales in post intervention samples in treatment group and decrease in placebo group were observed.

# Figure 3: Abundance of major bacterial orders

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342343


344

345

346

347

348



351

352

353

354

355

356

357

358

359

360

361

362

363


364

365

366

Family: The average % OTUs of family Prevotellaceae was 32.66% and 33.20% in pre and post intervention sample respectively in treatment group and 8.62% and 31.96% in placebo group. Significant increase was observed in OTUs of family Prevotellaceae in post intervention samples in placebo group. The average % OTUs of family Ruminococcaceae was 8.22% and 11.99% in pre and post intervention sample respectively in treatment group and 12.34% and 12.23% in placebo group. Increase in OTUs of family Ruminococcaceae in post intervention samples in treatment group and decrease in placebo group. The average % OTUs of family Bacteroidaceae was 4.09% and 4.58 % in pre and post intervention sample respectively in treatment group 22.85% and 9.44% in placebo group. Increase in OTUs of family Bacteroidaceae in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of family Lachnospiraceae was 6.14 % and 8.40 % in pre and post intervention sample respectively in treatment group and 6.79 % and 13.48 % respectively in placebo group. The average % OTUs of family Veillonellaceae was 7.47% and 5.72 % in pre and post intervention sample respectively in treatment group and 3.49 % and 7.15% in placebo group. Decrease in OTUs of family Veillonellaceae in post intervention samples in treatment group and increase in placebo group were observed. The average % OTUs of family Enterobacteriaceae was 4.69 % and 3.14 % in pre and post intervention sample respectively in treatment group and 9.79% and 2.41 % respectively in placebo group. A significant decrease was observed in OTUs of family Enterobacteriaceae in post intervention samples in placebo group. The average % OTUs of family Lactobacillaceae was 1.12% and 2.03% in pre and post intervention sample respectively in treatment group and 6.36 % and 3.22 % respectively in placebo group. Increase in OTUs of family Lactobacillaceae in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of family Bifidobacteriaceae was 1.74% and 3.55% in pre and post intervention sample respectively in treatment group and 7.71% and 1.61% respectively in placebo group. Increase in OTUs of family Bifidobacteriaceae in post intervention samples in treatment group and decrease in placebo group were observed.

Figure 4: Abundance of major bacterial families



**Genera:** The average % OTUs of genus *Prevotella* were 26.37% and 22.10% in pre and post intervention sample respectively in treatment group and 10.28% and 25.57% respectively in placebo group. Decrease in OTUs of genus *Prevotella* in post intervention samples in treatment group and an increase in placebo group was observed. The average % OTUs of

386

387

388

389

390

391

392

393

394

395

396

397

398 399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415


416

417

418

genus Bacteroides were 4.88% and 6.13% in pre and post intervention sample respectively in treatment group and 19.96% and 7.89% respectively in placebo group. An increase in OTUs of genus *Bacteroides* in post intervention samples in treatment group and decrease in placebo group were observed. Average % OTUs of genus Faecalibacterium were 6.56% and 6.87% in pre and post intervention sample respectively in treatment group and 9.23% and 8.01% respectively in placebo group. An increase in OTUs of genus Faecalibacterium in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of genus *Lactobacillus* were 1.21% and 2.59% in pre and post intervention sample respectively in treatment group and 7.33% and 3.49% respectively in placebo group. An increase in OTUs of genus *Lactobacillus* in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of genus Bifidobacterium were 1.67% and 4.44% in pre and post intervention sample respectively in treatment group and 6.03% and 1.42% respectively in placebo group. An increase in OTUs of genus Bifidobacterium in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of genus Bacillus were 0.01% and 0.04% in pre and post intervention sample respectively in treatment group and 0.001% and 0.001% respectively in placebo group. OTUs of Genus *Bacillus* in post intervention samples in treatment group were high while OTUs of genus Bacillus in placebo group were very low. The average % OTUs of genus Escherichia were 3.61% and 1.24% in pre and post intervention sample respectively in treatment group and 11.06% and 1.81% in placebo group. The average % OTUs of genus Sutterella were 3.05% and 2.22% in pre and post intervention sample respectively in treatment group and 3.60% and 1.68 % in placebo group. The average % OTUs of genus Dialister were 3.37% and 1.98% in pre and post intervention sample respectively in treatment group and 0.09% and 3.66% respectively in placebo group. A decrease in OTUs of genus Dialister was observed in post intervention samples in treatment group and increase in placebo group. The average % OTUs of genus Megamonas were 1.39% and 2.17% in pre and post intervention sample respectively in treatment group and 0.73% and 0.001% respectively in placebo group. An increase in OTUs of genus Megamonas was observed in post intervention samples in treatment group and decrease in placebo group. The average % OTUs of genus Roseburia were 0.82% and 0.45% in pre and post intervention sample respectively in treatment group and 1.18% and 2.46% in placebo group. A decrease in OTUs of genus *Roseburia* was observed in post intervention samples in treatment group and increase in placebo group. The average % OTUs of genus Megasphaera were 2.37% and 0.36% in pre and post intervention sample respectively in treatment group and 2.02% and 1.97% in placebo group. A decrease in OTUs of genus *Megasphaera* was observed in post intervention samples in both treatment and placebo group. The average % OTUs of genus *Lachnospira* were 0.42% and 0.34% in pre and post intervention sample respectively in treatment group and 1.49% and 2.83% in placebo group. An increase in OTUs of genus *Lachnospira* was observed in post intervention samples in treatment group and decrease in placebo group. The average % OTUs of genus *Blautia* were 0.25% and 0.40% in pre and post intervention sample respectively in treatment group and 0.12% and 0.25% in placebo group. An increase in OTUs of genus *Blautia* was observed in post intervention samples in both treatment and placebo group. The average % OTUs of genus Alistipes were 0.08% and 0.37% in pre and post intervention sample respectively in treatment group and 0.12% and 0.04% in placebo group. An increase in OTUs of genus Alistipes in post intervention samples in treatment group and decrease in placebo group were observed.

Figure 5: Abundance of major bacterial genera



# Cytokines levels

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448 449

450

451

452

453

454 455

456

457

458

459

460 461

462 463

464

465

466

Serum concentrations of different cytokines were assessed before and after intervention and results are expressed as Mean  $\pm$  SD. In the probiotic treated group serum levels of IL10 were  $3.23 \pm 1.22$  pg/ml and  $9.25 \pm 2.6$  pg/ml before and after intervention respectively with the difference being significant (p <0.05). In the placebo group serum IL10 levels were  $2.47 \pm 1.19$  pg/ml and  $2.97 \pm 1.67$  pg/ml before and after intervention respectively, this difference was not significant (p = ns). Results indicated that the secretion of IL-10 in IBD-UC patients was increased in B coagulans Unique IS2 group. In the treatment group serum IL6 levels were 34.13 ± 6.8 pg/ml and 17.64 ± 5.2pg/ml before and after intervention respectively with the difference being significant (p <0.05). In the placebo group serum IL6 levels were  $35.85 \pm 7.6$ pg/ml and  $28.49 \pm 6.4$ pg/ml before and after intervention respectively and this difference was not significant (p = ns). The observed results indicated that the secretion of IL-6 in IBD-UC patients was decreased in B coagulans Unique IS2 group. In the probiotic treated group, serum IL17 levels were  $42.82 \pm 6.9$ pg/ml and 28.57 ± 5.4pg/ml before and after intervention respectively with the difference being significant (p < 0.05). In the placebo group serum IL17 levels were  $36.73 \pm 13.73$  pg/ml and  $33.96 \pm 14.74$  pg/ml before and after intervention respectively with the difference not being significant (p = ns). The observed results indicated that the secretion of serum IL-17 was decreased in IBD-UC patients in the probiotic group. In the probiotic treated group serum IL23 levels were 938.39  $\pm$  56.57 pg/ml and 842.20  $\pm$  69.43 pg/ml before and after intervention respectively with the difference not being significant. In the placebo group serum IL23 levels were  $951.59 \pm 61.31$ pg/ml and  $932.02 \pm 43.30$  pg/ml before and after intervention respectively with the difference not being significant (p = ns).

In the treatment group serum IL-1 $\beta$  levels were 358.58  $\pm$  39.29 pg/ml and 267.28  $\pm$  33.88 pg/ml before and after intervention respectively with the difference being significant (p <0.05). In the placebo group serum IL-1 $\beta$  levels were 363.93  $\pm$  35.57 pg/ml and 382.59  $\pm$  37.50 pg/ml before and after intervention respectively with the difference not being significant (p = ns). The observed results indicated that the secretion of serum IL-1 $\beta$  in IBD-UC patients was increased in *B coagulans* Unique IS2 group. In the treatment group serum TNF-  $\alpha$  levels were 80.33  $\pm$  13.68 pg/ml and 69.16  $\pm$  14.79 pg/ml before and after intervention respectively with the difference not significant whereas in the placebo group serum TNF-  $\alpha$  levels were 76.35  $\pm$  14.72 pg/ml and 79.39  $\pm$  13.8 pg/ml before and after intervention respectively with the difference not being significant.

# Serum serotonin and dopamine levels:

In the treatment group serum serotonin level were  $121.48 \pm 15.52$  ng/ml and  $111.30 \pm 17.74$  ng/ml before and after intervention and the difference was not significant. In the placebo group serotonin level were  $118.12 \pm 19.25$  ng/ml and  $109.88 \pm 11.23$  ng/ml before and after intervention and the difference was not significant. In the treatment group serum dopamine level were  $8.51 \pm 2.52$  pg/ml and  $11.74 \pm 2.25$  pg/ml before and after intervention and the difference was not significant. In the placebo group dopamine level were  $8.48 \pm 2.89$  pg/ml and  $10.89 \pm 2.99$  pg/ml, before and after intervention and the difference was not significant. There were changes in serotonin and dopamine levels in the subjects before and after intervention but the difference was not significant.

Table 1: Serum Cytokines, serotonin and dopamine levels in pre and post intervention samples in treatment and placebo group

Cytokine (pg/ml)	Bacillus coagulans Unique IS2 group			Placebo group		
	Pre	Post	P value	Pre	Post	P value
IL-10	$3.23 \pm 1.22$	$9.25 \pm 2.6$	< 0.05	$2.47 \pm 1.19$	$2.97 \pm 1.67$	NS
IL-6	$34.13 \pm 6.8$	$17.64 \pm 5.2$	< 0.05	$35.85 \pm 7.6$	$28.49 \pm 6.4$	NS
IL-17	$42.82 \pm 6.9$	$28.57 \pm 5.4$	< 0.05	$36.73 \pm 13.7$	$33.96 \pm 14.74$	NS
IL-23	$938.39 \pm 56.5$	$842.20 \pm 69.4$	NS	$951.59 \pm 61.3$	$932.02 \pm 43.30$	NS
IL-1β	$358.58 \pm 39.2$	$267.28 \pm 33.8$	< 0.05	$363.93 \pm 35.5$	$382.59 \pm 37.50$	NS
TNF- α	$80.33 \pm 13.6$	$69.16 \pm 14.7$	NS	$76.35 \pm 14.7$	$79.39 \pm 13.8$	NS
Serotonin (ng/ml)	$121.48 \pm 15.5$	$111.30 \pm 17.7$	NS	118.12 ± 19.2	$109.88 \pm 11.23$	NS
Dopamine (pg/ml)	$8.51 \pm 2.52$	$11.74 \pm 2.2$	NS	$8.48 \pm 2.89$	$10.89 \pm 2.99$	NS

#### **Effect on disease symptoms**

Symptoms of disease were assessed based on patient complaint and SCCAI score was calculated for IBD-UC patients as per standard protocol. The decrease in the SCCAI score indicates the reduction in the severity of symptoms and increase in the score indicates the augmentation in the severity of the symptom of UC. In this study reduction of 1 value in SCCAI score was considered as decrease in SCCAI score. The SCCAI score was decreased post intervention in 43.75~% of the patients in the probiotic treated group which was significantly high (p <0.05) as compared to placebo where the decrease in SCCAI score was reported in 28.57~% patients.

## Effect on physical, behavioral and psychological parameters

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

The enrolled subjects were assessed before and after intervention for the different physical symptoms, behavioral and psychological symptoms including stiff or tense muscles, heartburn, headache, shakiness or tremor, sleep problem, difficulty in completing work, procrastination, overwhelming, feeling of depression, trouble relaxing, nervousness, poor concentration, quick temper and restlessness. All the symptoms were evaluated based on scores, the decrease in the score indicates the reduction in the severity of symptoms and increase in the score indicates the augmentation in the severity of the symptom. In this study the complaint of muscles stiffness was reduced post intervention in 41.66 % and 29.16 % subjects in the treatment and placebo group respectively and the difference between the groups was significant (p<0.05). The complaint of heartburn was reduced post intervention in 43.75 % and 31.25 % subjects in the treatment and placebo group respectively and the difference between the groups was significant (p<0.05). The complaints of headache were reduced post intervention in 37.5 % and 33.33 % subjects in the probiotic and placebo group respectively with no significant difference between groups. The complaint of shakiness or tremor was reduced post intervention in 33.33 % and 31.25 % subjects in the treatment and placebo group with no significant difference between groups.

The complaint of sleep problem was reduced post intervention in 41.66 % and 27.08 % subjects in the treatment and placebo group respectively with the difference between groups being significant (p <0.05). The complaint of procrastination was reduced in 31.25 % subjects and 35.4 % subjects in the treatment and placebo group respectively with no significant difference between groups. The complaints of difficulty in completing work or assignments was decreased post intervention in 37.5 % subjects and 27.08 % subjects in the probiotic treated and placebo group respectively with the difference between groups being significant (p < 0.05). The complaints of overwhelming was reduced post intervention in 41.66 % and 31.25 % subjects in the treatment and placebo group respectively and the difference between placebo and treatment groups was significant (p <0.05). The complaints of trouble relaxing was reduced post intervention in 37.5 % and 27.08 % subjects in the treatment group and placebo group respectively with the difference between groups being significant (p <0.05). The complaint of nervousness was reduced post intervention in 33.33 % and 29.16 % subjects in the treatment and placebo group respectively with no significant difference between groups. The complaints of depression was reduced post intervention in 33.33 % and 31.25 % subjects in the treatment and placebo group respectively with no significant difference between groups. The complaints of poor concentration was reduced

post intervention in 47.91 % and 33.3 % subjects in the treatment group and placebo group respectively with the difference between groups being significant (p<0.05). The complaints of quick temper was reduced post intervention in 45.83 % and 39.58 % subjects in the treatment group and placebo group respectively with no significant difference. The complaints of restlessness was reduced post intervention in 47.91 % and 35.4 % subjects in the treatment group and placebo group respectively with the difference between groups being significant (p<0.05). The observed results exhibited improvement in various physical, behavioral and psychological symptoms of enrolled IBD subjects in the treatment group.

Table 2: Post intervention decrease in symptoms in the enrolled subjects for different physical, behavioral and psychological parameters

Physical, behavioural and psychological parameters		ion decrease in symp of total subjects)	otoms
	Bacillus coagulans Unique IS2 group	Placebo group	P value
Muscles stiffness	41.66 %	29.16 %	< 0.05
Heartburn	43.75	31.25 %	< 0.05
Headache	37.5 %	33.33 %	NS
Shakiness or tremor	33.33 %	31.25 %	NS
Sleep problem	41.66 %	27.08 %	< 0.05
Procrastination	31.25 %	35.4 %	NS
Difficulty in completing	37.5 %	27.08 %	< 0.05
work or assignments			
Overwhelming	41.66 %	31.25 %	< 0.05
Trouble relaxing	37.5 %	27.08 %	< 0.05
Nervousness	33.33 %	29.16 %	NS
Depression	33.33 %	31.25 %	NS
Poor concentration	47.91 %	33.3 %	< 0.05
Quick temper	45.83 %	39.58 %	NS
Restlessness	47.91 %	35.4 %	< 0.05

**Safety evaluations:** During and after intervention no adverse events were observed, recorded and reported in the study which further established the safety of *B coagulans* Unique IS2.

537 Discussion

Targeted microbiota intervention through probiotics and fecal microbiota transplantation are considered as effective therapeutic methods for IBD<sup>12,33</sup>. Mechanisms of action of probiotics in IBD prevention include increase in beneficial bacteria, inhibition of pathogenic bacteria, immuno-modulation, augmentation of anti-inflammatory responses and enhancement of the intestinal barrier function<sup>14</sup>. *Bacillus* species are high heat resistance, acid tolerance and they can survive considerably better than other probiotics in gastric conditions<sup>34,35</sup>. *B coagulans* Unique IS-2 is a non-toxic commercial probiotic strain with proven safety and efficacy, long shelf life and stability at room temperature<sup>24</sup>. Whole genome sequence analysis of *B. coagulans* Unique IS-2 has corroborated its safety with the absence of any toxin genes<sup>36</sup>. In this study, no severe adverse event was reported, which establish the safety of *B. coagulans* Unique IS-2. Safety and therapeutic efficacy of *B coagulans* Unique IS-2 has been proven in different disease including Irritable Bowel Syndrome in adult<sup>27</sup> and children<sup>25</sup>, acute-diarrhea<sup>26</sup>, abdominal pain<sup>37</sup>, constipation<sup>27</sup>, oral health<sup>38</sup>, bacterial vaginosis<sup>26</sup>, anti-hypercholesterolemic effect<sup>22</sup>and liver cirrhosis. This strain also showed anti-inflammatory<sup>24</sup> and anti-proliferative effects<sup>39</sup>.

Post intervention, significant detection of *Bacillus coagulans* in the probiotic treated group demonstrating that this probiotic strain was able to survive in GI tract of IBD patients. Beneficial bacteria provide protection to host against colonization of harmful bacteria and suppress the growth of pathogens by imposing competition for shared niches and nutrients<sup>40</sup>. Results of the present study indicated that *B coagulans* Unique IS-2 was able to modulate the gut microbiota by increasing beneficial bacteria. Another study also reported that consumption of *B. coagulans* was capable of restoring the microbial imbalance<sup>41</sup> and able to increase populations of *Lactobacillus* and *Bifidobacteria*<sup>42,43</sup> possibly by consuming free oxygen in the intestine and reduces redox reactions, creating an unfavorable anaerobic and acidic environment to various pathogens<sup>43</sup>.

Results of the metagenomics analysis revealed that phylum Firmicutes, Bacteriodetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were abundant in both the study group which are earlier reported dominated in Indian gut<sup>44,45</sup>. An increase in the abundance of phylum Firmicutes and Bacteriodetes was observed in post intervention sample in both groups. Decrease in abundance of phylum Proteobacteria and Actinobacteria was observed in post intervention sample in both groups. Other studies also reported decrease in Bacteroides and Firmicutes and increase in Proteobacteria and Actinobacteria in GI

disease<sup>31,46</sup>. It is believed that inflammation is an oxidative state which might promote the outgrowth of aerotolerant taxa such as Proteobacteria and Actinobacteria<sup>47</sup>.

571

572 573

574

575

576 577

578

579

580

581

582

583

584

585

586 587

588

589 590

591 592

593

594

595

596

597 598

599 600

601 602

603

604

The abundance of Lactobacillus, Bifidobacterium and Bacillus genera were increased in post intervention samples in treatment group and decrease in placebo group. Lactobacillus and *Bifidobacteria* are among the first colonizers of newborns<sup>48</sup> and are known for their beneficial effects<sup>49</sup>. The observed high abundance of *Lactobacillus*, *Bifidobacterium* and Bacillus genera in treatment group indicated that given probiotic help the gut in restoring these beneficial bacteria. Other studies reported decreased abundance of Faecalibacterium in We observed an increase in abundance of genus Faecalibacterium in post intervention samples in treatment group and decrease in placebo group which indicates the given probiotic help the gut in restoring them. Bacterial genera Lactobacillus, Bifidobacterium, and Faecalibacterium have been reported to be protective for mucosal inflammation in the host<sup>11,52</sup> via several mechanisms, including the up-regulation of the antiinflammatory cytokine, and down-regulation of inflammatory cytokines<sup>53</sup>. Studies reported decrease in the genera Bacteriodes in IBD14,54. We observed an increase in abundance of genus Bacteroides in post intervention samples in treatment group and decrease in placebo group which indicates that the given probiotic intervention may help to restore the genus Bacteroides in enrolled IBD patients. A decrease in the abundance of bacterial genera Dialister, Roseburia, Megasphaera was observed in post intervention samples in treatment group and increase in placebo group. A decrease in the abundance of Blautia species in the IBD patients was reported<sup>55</sup>. We observed an increase in OTUs of genus *Blautia* in post intervention samples in both treatment and placebo group. An increase in abundance of genus Alistipes in post intervention samples in treatment group and decrease in placebo group were observed. Gut microbiota study in the IBD patients reported that some of the Faecalibacterium, Bacteroides and Alistipes species have shown significant contribution to metabolic pathway transcription<sup>56</sup>. The abundance of some of bacterial taxon was low but these may play important role in gut function as reported earlier<sup>57</sup>.

The improper host immune response against GI microbiota is considered to be the main reason in causing severe inflammation<sup>40</sup>. Studies have reported the changes in the serum levels of anti- inflammatory cytokine (IL-10) and pro- inflammatory cytokines (IL-6, IL-12, TNF- $\alpha$ , INF- $\gamma$ ) in GI disorders<sup>58</sup>. However, the serum cytokine profiling of IBD patients remains less reported. In the present study significant increase was observed in IL-10 levels in treatment group which indicated that the probiotic strain was able to increase the secretion of IL-10 in IBD patients in the treatment group. Other studies have reported the association of

IBD patients with anti-inflammatory cytokines IL-10<sup>59</sup> and IL-10 secretion increased during disease recovery in IBD patients<sup>60</sup>. It is also reported that inactivation of IL-10 leads to increased release of pro-inflammatory cytokines <sup>61</sup>.

In the present study we observed the significant decrease in IL6 (p <0.05), IL17 (p <0.05), IL23 (p <0.05), and IL-1 $\beta$  (p <0.05), TNF-  $\alpha$  in treatment group which indicated the probiotic intervention was able to modulate the secretion of pro-inflammatory cytokines. Previous studies have reported increased expression of IL-6 may be an intestinal inflammatory mediator of IBD<sup>64</sup>. Studies have reported that the expression of IL-6 was predominantly detected in IBD and an association between serum levels of IL-6 and disease activity<sup>62</sup>. A study reported IL6 in active UC 26 +/- 10 pg/ml and in inactive UC < 10 pg/ml<sup>63</sup> and this suggested that increased expression of IL-6 may be an intestinal inflammatory mediator of IBD. IL-17 induces the production of many other pro-inflammatory cytokines, including IL-6, TNF- $\alpha$ , and IL-1 $\beta$ , which leads to localizing and amplifying inflammation. IL-17 was reported to be increased in intestinal tissue and serum of IBD patients<sup>64,65</sup>. IL-1β is a pro-inflammatory cytokines play important role in the inflammation in patients with IBD and an elevation in IL-1 $\beta$  levels are associated with increased disease severity<sup>66-68</sup>. Studies reported that the improper level of serotonin and dopamine increases the severity of IBD<sup>69</sup>. Serum serotonin and dopamine were also evaluated in this study but no significant change was observed in both groups.

Results of the study indicated that *B coagulans* Unique IS-2 along with SMT was able to reduce the severity of symptom and improve physical and psychological parameters in IBD patient in the treatment group. These results are similar to another study which reported that a probiotic mixture (VSL#3) reduced the expression of inflammatory cytokines and the severity of disease in UC patients<sup>70</sup>. A meta-analysis also reported that probiotics can benefit IBD treatment during combined use of probiotics and standard therapy<sup>71</sup>. A study with *B. coagulans* Unique IS-2 in children with functional abdominal pain indicated reduction of abdominal pain in the probiotic treated group<sup>37</sup>. Another study reported *B. coagulans* Unique IS-2 was effective in the treatment of IBS with a significant decrease in the intensity of pain in the probiotic treated group<sup>25</sup>. Probiotics can reduce inflammation and disease symptoms by modulation of the mucosal immune system, increased intestinal barrier function, competitive prohibition of pathogens, production of antimicrobial factors<sup>72</sup> amplification of the intestinal tight junctions to stabilize the permeability, normalize bowel movements and reduce visceral hypersensitivity<sup>73-75</sup>.

## **Summary and Conclusion**

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657 658

659

660

661

662

663

664

665

666

667

668 669

670

The results of the study showed that the *B coagulans* Unique IS-2 is able to survive in GI tract of IBD patients. B. coagulans Unique IS-2 was able to enhance bacterial genera Lactobacillus, Bifidobacterium, Faecalibacterium, Bacteroides, Megamonas, Lachnospira, Blautia and Alistipes in post intervention samples in the treatment group. A decrease in bacterial genera Sutterella, Dialister, Roseburia and Megasphaera was observed in post intervention samples in the treatment group. Variable alterations were also observed in the abundance of different bacterial taxon including phylum, class, order, family, and genus in the post intervention sample of the treatment group. B coagulans Unique IS-2 was able to modulate the secretion of serum cytokines in IBD patients. The level of IL-10 was increased significantly post intervention in treatment group. The secretion of cytokines, IL-6, IL-1β, TNF- α, IL -17 and IL -23 were variably decreased post intervention in the treatment group. No significant change in serum serotonin and dopamine was observed in both treatment and placebo groups. A reduction in the severity of symptoms of disease and significant improvement in the physical and psychological parameter were observed post intervention in enrolled subjects in the treatment group. Observed results demonstrated that B coagulans Unique IS2 showed beneficial effect in IBD-UC patients when administered along with standard medical treatment (SMT). Study was registered with Clinical Trials Registry India (CTRI) - (CTRI registration No. - CTRI/2019/11/022087). Conflict of interest statement: RSM and JN are employed by manufacturer of probiotics

(Unique Biotech Ltd) and they wish to state that the study was conducted independently with no intervention on their part during the study. All other authors declare no conflict of interest. **Author Contribution:** VDB- Recruited the subjects, carried out experiments, analyzed data and wrote final manuscript, DD - carried out experiments and analyzed the data, PS - carried out experiments and analyzed the data. SK clinical assessment and monitoring of subjects, RSM, JN – drafted study proposal and manuscript, VA- clinical assessment and monitoring of subjects, designed the trial, supervised the study. RC -conceptualizes the study, finalized study proposal, designed the trial and supervised the study. All the authors read and revised the manuscript and approve the final manuscript.

**Acknowledgement:** Authors acknowledge the financial support from Unique Biotech Ltd, Hyderabad, India. Help of Mr. Surender Singh (Laboratory Technician) in microbial culture

media and reagent preparation is also acknowledged.

## References

- 1. Acharyya BC. Incidence of Inflammatory Bowel Disease in a Tertiary Centre of Eastern
- India. ARGH; 9. Epub ahead of print 26 July 2018. DOI:
- 674 10.19080/ARGH.2018.09.555774.
- 675 2. Kedia S, Ahuja V. Is the emergence of inflammatory bowel disease a prime example of 676 'the third epidemiological transition'? *Indian J Gastroenterol* 2018; 37: 183–185.
- 3. Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. *Intest Res* 2017; 15: 138–141.
- 4. Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great
   Shift East. *Inflamm Intest Dis* 2017; 2: 102–115.
- 5. Kim YS, Jung S-A, Lee K-M, et al. Impact of inflammatory bowel disease on daily life:
- an online survey by the Korean Association for the Study of Intestinal Diseases. *Intest Res* 2017; 15: 338–344.
- 684 6. Sigall-Boneh R, Levine A, Lomer M, et al. Research Gaps in Diet and Nutrition in
- Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. *J Crohns Colitis* 2017; 11: 1407–1419.
- 7. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. *Curr Pharm Des* 2014; 20: 1082–1096.
- 8. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. *Curr Mol Med* 2008; 8: 247–252.
- Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances
   in Biologic Therapies. *Immune Netw* 2017; 17: 25–40.
- 10. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol* 2018; 11: 1–10.
- 11. Zuo T, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of
   Inflammatory Bowel Disease. Front Microbiol 2018; 9: 2247.
- 12. Dong L-N, Wang M, Guo J, et al. Role of intestinal microbiota and metabolites in inflammatory bowel disease. *Chin Med J (Engl)* 2019; 132: 1610–1614.
- 700 13. Sun Y, Li L, Xia Y, et al. The gut microbiota heterogeneity and assembly changes associated with the IBD. *Sci Rep* 2019; 9: 440.
- 702 14. Khan I, Ullah N, Zha L, et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome.
- 704 *Pathogens* 2019; 8: 126.
- 15. Manocha M, Khan WI. Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. *Clin Transl Gastroenterol* 2012; 3: e13.
- 16. O'Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav Brain Res* 2015; 277: 32–48.
- 709 17. Tolstanova G, Deng X, Ahluwalia A, et al. Role of Dopamine and D2 Dopamine
- Receptor in the Pathogenesis of Inflammatory Bowel Disease. *Dig Dis Sci* 2015; 60: 2963–2975.
- 712 18. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-713 enteric microbiota axis. *Nat Rev Gastroenterol Hepatol* 2009; 6: 306–314.

- 714 19. Reber SO. Stress and animal models of inflammatory bowel disease—An update on the
- role of the hypothalamo–pituitary–adrenal axis. *Psychoneuroendocrinology* 2012; 37: 1– 19.
- 717 20. Sudha M, Chauhan P, Dixit K, et al. Molecular Typing and Probiotic Attributes of a New
- Strain of Bacillus coagulans Unique IS-2: a Potential Biotherapeutic Agent. *undefined*,
- 719 https://www.semanticscholar.org/paper/Molecular-Typing-and-Probiotic-Attributes-of-a-
- 720 New-Sudha-Chauhan/f8bbf999bc57cb022d282e9ad13442f877914db7 (2010, accessed 28 July 2021).
- 722 21. Konuray G, Erginkaya Z. Potential Use of Bacillus coagulans in the Food Industry.
   723 Foods 2018; 7: 92.
- 724 22. Ratna Sudha M, Radkar N, Maurya A. Effect of supplementation of probiotic bacillus
- coagulans unique IS-2 (ATCC PAT-11748) on hypercholesterolemic subjects: A clinical
- 726 study. *International Journal of Probiotics and Prebiotics* 2011; 6: 89–94.
- 727 23. Ratna Sudha M, Bhonagiri S. Efficacy of Bacillus coagulans strain unique IS-2 in the
- treatment of patients with acute diarrhea. *International Journal of Probiotics and Prebiotics* 2012; 7: 33–37.
- 730 24. Sudha RM, Sunita M, Sekhar BM. Safety studies of bacillus coagulans unique IS-2 in
- rats: Morphological, biochemical and clinical evaluations. *International Journal of*
- 732 *Probiotics & Prebiotics* 2016; 11: 43+.
- 733 25. Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of Bacillus coagulans Unique IS2 in
- treatment of irritable bowel syndrome in children: a double blind, randomised placebo
- controlled study. *Benef Microbes* 2018; 9: 563–572.
- 736 26. Ratna Sudha M, Yelikar KA, Deshpande S. Clinical Study of Bacilluscoagulans Unique
- 737 IS-2 (ATCC PTA-11748) in the Treatment of Patients with Bacterial Vaginosis. *Indian J Microbiol* 2012; 52: 396–399.
- 739 27. Madempudi RS, Neelamraju J, Ahire JJ, et al. Bacillus coagulans Unique IS2 in
- 740 Constipation: A Double-Blind, Placebo-Controlled Study. *Probiotics Antimicrob*
- 741 *Proteins* 2020; 12: 335–342.
- 742 28. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. *Gut* 1998; 43: 29–32.
- Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL).
   Psychological Measurements in Psychopharmacology 1974; 7: 79–110.
- 746 30. Kleppang AL, Hagquist C. The psychometric properties of the Hopkins Symptom
- Checklist-10: a Rasch analysis based on adolescent data from Norway. Fam Pract 2016;
- 748 33: 740–745.
- 749 31. Bamola VD, Ghosh A, Kapardar RK, et al. Gut microbial diversity in health and disease:
- experience of healthy Indian subjects, and colon carcinoma and inflammatory bowel
- disease patients. *Microb Ecol Health Dis* 2017; 28: 1322447.
- 752 32. Ahmed N, Daniel B, Varghese J, et al. Oropharyngeal microbiome of an HIV-positive
- patient. Microbial Pathogenesis 2020; 139: 103805.
- 754 33. Hudson LE, Anderson SE, Corbett AH, et al. Gleaning Insights from Fecal Microbiota
- 755 Transplantation and Probiotic Studies for the Rational Design of Combination Microbial
- 756 Therapies. Clin Microbiol Rev 2017; 30: 191–231.

- 757 34. Hyronimus B, Le Marrec C, Sassi AH, et al. Acid and bile tolerance of spore-forming lactic acid bacteria. *Int J Food Microbiol* 2000; 61: 193–197.
- 759 35. Keller D, Verbruggen S, Cash H, et al. Spores of Bacillus coagulans GBI-30, 6086 show
- high germination, survival and enzyme activity in a dynamic, computer-controlled in vitro model of the gastrointestinal tract. *Benef Microbes* 2019; 10: 77–87.
- 36. Upadrasta A, Pitta S, Madempudi RS. Draft Genome Sequence of the Spore-Forming
   Probiotic Strain Bacillus coagulans Unique IS-2. *Genome Announc* 2016; 4: e00225-16.
- 764 37. Saneian H, Pourmoghaddas Z, Roohafza H, et al. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. 766 Gastroenterol Hepatol Bed Bench 2015; 8: 56–65.
- 767 38. K MJ, Shenoy N, Talwar A, et al. Clinical effect of pro-biotic containing Bacillus coagulans on plaque induced gingivitis □: A randomised clinical pilot study. *Journal of Health and Allied Sciences NU* 2017; 07: 007–012.
- 39. Madempudi RS, Kalle AM. Antiproliferative Effects of Bacillus coagulans Unique IS2
   in Colon Cancer Cells. *Nutr Cancer* 2017; 69: 1062–1068.
- 40. Kho ZY, Lal SK. The Human Gut Microbiome A Potential Controller of Wellness and
   Disease. Front Microbiol 2018; 9: 1835.
- 41. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA* 2012; 307: 1959–1969.
- 42. Ara K, Meguro S, Hase T, et al. Effect of Spore-bearing Lactic Acid-forming Bacteria (
   Bacillus coagulans SANK 70258) Administration on the Intestinal Environment,
- Defecation Frequency, Fecal Characteristics and Dermal Characteristics in Humans and Rats. *Microbial Ecology in Health and Disease* 2002; 14: 4–13.
- 781 43. Cao J, Yu Z, Liu W, et al. Probiotic characteristics of Bacillus coagulans and associated 782 implications for human health and diseases. *Journal of Functional Foods* 2020; 64: 783 103643.
- 44. Jain A, Li XH, Chen WN. Similarities and differences in gut microbiome composition correlate with dietary patterns of Indian and Chinese adults. *AMB Expr* 2018; 8: 104.
- 45. Gupta A, Dhakan DB, Maji A, et al. Association of Flavonifractor plautii, a Flavonoid Degrading Bacterium, with the Gut Microbiome of Colorectal Cancer Patients in India.
   mSystems; 4: e00438-19.
- 789 46. Ryan FJ, Ahern AM, Fitzgerald RS, et al. Colonic microbiota is associated with 790 inflammation and host epigenomic alterations in inflammatory bowel disease. *Nat Commun* 2020; 11: 1512.
- 792 47. Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol* 2017; 14: 573–584.
- 794 48. Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. *Nat Commun* 2015; 6: 6528.
- 49. Flint HJ, Scott KP, Duncan SH, et al. Microbial degradation of complex carbohydrates in
   the gut. *Gut Microbes* 2012; 3: 289–306.
- 50. Becker C, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel Disease. *ILAR J* 2015; 56: 192–204.

- 51. Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. *J Clin Microbiol* 2014; 52: 398–406.
- 52. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* 2011; 60: 631–637.
- 53. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 2008; 105: 16731–16736.
- 54. Nemoto H, Kataoka K, Ishikawa H, et al. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. *Dig Dis Sci* 2012; 57: 2955–2964.
- 55. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe* 2014; 15: 382–392.
- 56. Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nat Microbiol* 2018; 3: 337–346.
- 57. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174–180.
- 58. Bennet SMP, Polster A, Törnblom H, et al. Global Cytokine Profiles and Association
   With Clinical Characteristics in Patients With Irritable Bowel Syndrome. Am J
   Gastroenterol 2016; 111: 1165–1176.
- 59. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clin Gastroenterol Hepatol* 2006; 4: 754–759.
- 60. Mitsuyama K, Tomiyasu N, Takaki K, et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase.

  Mediators Inflamm 2006; 2006: 26875.
- 61. Ma X, Yan W, Zheng H, et al. Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells. *F1000Res* 2015; 4: F1000 Faculty Rev-1465.
- 62. Mavropoulou E, Mechie N-C, Knoop R, et al. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. *PLOS ONE* 2020; 15: e0233811.
- 63. Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. *J Clin Gastroenterol* 1995; 20: 123–126.
- 64. Kuwabara T, Ishikawa F, Kondo M, et al. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. *Mediators of Inflammation* 2017; 2017: e3908061.
- 65. Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, et al. Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. *Cureus* 2017; 9: e1177.
- 66. Mao L, Kitani A, Strober W, et al. The Role of NLRP3 and IL-1β in the Pathogenesis of
   Inflammatory Bowel Disease. *Front Immunol* 2018; 9: 2566.
- 67. Coccia M, Harrison OJ, Schiering C, et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. *J Exp Med* 2012; 209: 1595–1609.

- 68. Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. *Gut* 1990; 31: 686–689.
- 69. Marcus MM, Jardemark K, Malmerfelt A, et al. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence. *Synapse* 2012; 66: 277–290.
- 70. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol* 2010; 105: 2218–2227.
- 71. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review. *Journal of Cellular Physiology* 2018; 233: 2091–2103.
- 72. Schlee M, Harder J, Köten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. *Clin Exp Immunol* 2008; 151: 528–535.
- 73. Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol* 2015; 21: 3072–3084.
- 74. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. *Nat Rev Gastroenterol Hepatol* 2010; 7: 503–514.
- 75. Korterink JJ, Ockeloen L, Benninga MA, et al. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. *Acta Paediatr* 2014; 103: 365–372.